大麻二酚辅助治疗结节性硬化症耐药性癫痫的随机对照试验
这项双盲安慰剂对照随机临床试验纳入224例1-65岁结节性硬化症相关耐药性癫痫患者,评估口服大麻二酚25 mg/kg/天和50 mg/kg/天 versus 安慰剂的疗效与安全性。主要终点为治疗期间TSC相关癫痫发作数较基线的变化。结果显示两种剂量均显著优于安慰剂,25 mg/kg/天安全性优于50 mg/kg/天。
要点
- 大麻二酚25 mg/kg/天和50 mg/kg/天均显著减少TSC相关癫痫发作,优于安慰剂。
- 25 mg/kg/天剂量安全性优于50 mg/kg/天,不良事件发生率更低。
- 常见不良事件为腹泻和嗜睡,大麻二酚组肝转氨酶升高发生率为18.9%。
核心结论
- 大麻二酚显著减少TSC相关癫痫发作,优于安慰剂。
- 25 mg/kg/天剂量安全性优于50 mg/kg/天剂量。
研究设计与样本
- 双盲、安慰剂对照随机临床试验(GWPCARE6),2016年4月6日至2018年10月4日入组,随访至2019年2月15日。
- 在澳大利亚、波兰、西班牙、荷兰、英国和美国的46个中心开展。
- 纳入224例1-65岁临床诊断TSC且药物难治性癫痫患者,基线4周内至少8次TSC相关发作且至少3周有发作,正在服用至少1种抗癫痫药物。
- 随机分为口服大麻二酚25 mg/kg/天(75例)、50 mg/kg/天(73例)或匹配安慰剂(76例),治疗16周。
主要发现
- 主要终点发作数较基线减少百分比:CBD25组48.6%(95%CI 40.4%-55.8%),CBD50组47.5%(95%CI 39.0%-54.8%),安慰剂组26.5%(95%CI 14.9%-36.5%)。
- 较安慰剂的减少百分比:CBD25组30.1%(95%CI 13.9%-43.3%;P < .001),CBD50组28.5%(95%CI 11.9%-42.0%;名义P = .002)。
- 最常见不良事件为腹泻(安慰剂组19例[25%],CBD25组23例[31%],CBD50组41例[56%])和嗜睡(安慰剂组7例[9%],CBD25组10例[13%],CBD50组19例[26%]),大麻二酚组发生率高于安慰剂。
- 因不良事件停药:CBD25组8例,CBD50组10例,安慰剂组2例。
- 大麻二酚组28例(18.9%)出现肝转氨酶升高,安慰剂组无。
临床怎么用
- 对于TSC相关药物难治性癫痫患者,可考虑加用大麻二酚25 mg/kg/天,因其疗效显著且安全性优于50 mg/kg/天。
- 治疗期间需监测腹泻、嗜睡及肝转氨酶水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as tuberous sclerosis complex (TSC). OBJECTIVE: To evaluate efficacy and safety of 25-mg/kg/day and 50-mg/kg/day cannabidiol dosages vs placebo against seizures associated with TSC. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled randomized clinical trial (GWPCARE6) enrolled patients between April 6, 2016, and October 4, 2018; follow-up was completed on February 15, 2019. The trial was conducted at 46 sites in Australia, Poland, Spain, the Netherlands, United Kingdom, and United States. Eligible patients (aged 1-65 years) were those with a clinical diagnosis of TSC and medication-resistant epilepsy who had had at least 8 TSC-associated seizures during the 4-week baseline period, with at least 1 seizure occurring in at least 3 of the 4 weeks, and were currently taking at least 1 antiepileptic medication. INTERVENTIONS: Patients received oral cannabidiol at 25 mg/kg/day (CBD25) or 50 mg/kg/day (CBD50) or a matched placebo for 16 weeks. MAIN OUTCOMES AND MEASURES: The prespecified primary outcome was the change from baseline in number of TSC-associated seizures for cannabidiol vs placebo during the treatment period. RESULTS: Of 255 patients screened for eligibility, 31 were excluded and 224 were randomized. Of the 224 included patients (median [range] age, 11.4 [1.1-56.8] years; 93 female patients [41.5%]), 75 were randomized to CBD25, 73 to CBD50, and 76 to placebo, with 201 completing treatment. The percentage reduction from baseline in the type of seizures considered the primary end point was 48.6% (95% CI, 40.4%-55.8%) for the CBD25 group, 47.5% (95% CI, 39.0%-54.8%) for the CBD50 group, and 26.5% (95% CI, 14.9%-36.5%) for the placebo group; the percentage reduction from placebo was 30.1% (95% CI, 13.9%-43.3%; P < .001) for the CBD25 group and 28.5% (95% CI, 11.9%-42.0%; nominal P = .002) for the CBD50 group. The most common adverse events were diarrhea (placebo group, 19 [25%]; CBD25 group, 23 [31%]; CBD50 group, 41 [56%]) and somnolence (placebo group, 7 [9%]; CBD25 group, 10 [13%]; CBD50 group, 19 [26%]), which occurred more frequently with cannabidiol than placebo. Eight patients in CBD25 group, 10 in CBD50 group, and 2 in the placebo group discontinued treatment because of adverse events. Twenty-eight patients taking cannabidiol (18.9%) had elevated liver transaminase levels vs none taking placebo. CONCLUSIONS AND RELEVANCE: Cannabidiol significantly reduced TSC-associated seizures compared with placebo. The 25-mg/kg/day dosage had a better safety profile than the 50-mg/kg/day dosage. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02544763.
引用
- Thiele EA, Bebin EM, Bhathal H, et al. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 33346789. doi:10.1001/jamaneurol.2020.4607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。